Choreo LLC Has $1.78 Million Stock Holdings in GSK plc (NYSE:GSK)

Choreo LLC decreased its holdings in shares of GSK plc (NYSE:GSK) by 3.5% in the fourth quarter, Holdings Channel reports. The firm owned 52,751 shares of the pharmaceutical company’s stock after selling 1,929 shares during the quarter. Choreo LLC’s holdings in GSK were worth $1,776,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GSK. Eastern Bank bought a new position in GSK during the third quarter worth about $26,000. Crews Bank & Trust bought a new position in GSK during the fourth quarter worth about $26,000. ST Germain D J Co. Inc. lifted its stake in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. lifted its stake in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Finally, Concord Wealth Partners lifted its stake in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the period. Institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

Shares of GSK stock opened at $36.03 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The firm has a market cap of $74.68 billion, a P/E ratio of 23.40, a P/E/G ratio of 1.38 and a beta of 0.64. The firm has a 50 day simple moving average of $34.21 and a 200 day simple moving average of $37.60. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 7.97% and a return on equity of 50.62%. Sell-side analysts predict that GSK plc will post 3.92 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be issued a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.36%. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is currently 96.10%.

Analysts Set New Price Targets

A number of brokerages have commented on GSK. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and cut their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday. Six research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.